Notable Upgrades: Marathon Oil (MRO), BioCryst (BCRX), DexCom (DXCM), (AMZN), Eagle Pharmaceuticals (EGRX)

Analysts at Morgan Stanley (MS) are out with a report this morning upgrading shares of Marathon Oil Corporation (MRO) with an ‘Overweight‘ from ‘Equal-Weight‘ rating.

Marathon Oil Corp. shares are currently priced at 6.96x this year’s forecasted earnings, which makes them inexpensive compared to the industry’s 11.38x earnings multiple. Ticker has a t-12 price-to-sales ratio of 1.89. EPS for the same period is $4.46.

In the past 52 weeks, shares of Houston Texas-based company have traded between a low of $24.28 and a high of $41.92 and are now at $31.05. Shares are down 14.24% year-over-year ; up 8.68% year-to-date.

Analysts at BofA/Merrill (BAC) upgraded their rating on the shares of BioCryst Pharmaceuticals, Inc. (BCRX). In a research note published on Monday, the firm lifted the name with a ‘Neutral‘ from ‘Underperform‘ rating and set a 12-month base case estimate of $12 from $8 per share.

On valuation measures, BioCryst Pharmaceuticals Inc. shares have a P/E-Growth ratio of 0.62. Price/Sales for the same period is 51.98 while EPS is ($0.68). Currently there are 9 analysts that rate BCRX a ‘Buy‘, 1 rates it a ‘Hold‘. No analyst rates it a ‘Sell‘. BCRX has a median Wall Street price target of $18.00 with a high target of $24.00.

DexCom, Inc. (DXCM) was reiterated a ‘Outperform’ by Wedbush analysts on Monday. The broker also raised its price target on the stock to $80 from $73.

DXCM shares recently gained $0.80 to $68.20. In the past 52 weeks, shares of San Diego, California-based medical device company have traded between a low of $28.09 and a high of $68.91. Shares are up 87.07% year-over-year and 22.43% year-to-date. Inc. (AMZN) was reiterated as ‘Neutral’ with a $395 from $330 price target on Monday by Wedbush.

About 1.7 million shares of have exchanged hands as of 1:01 pm EDT today, compared to its average trading volume of about 3.55 million shares a day. The stock began trading this morning at $378.55 to currently trade 10 points, or 2.66% higher from the prior days close of $375.56. On an intraday basis it has gotten as low as $377.00 and as high as $385.00.

Amazon shares have advanced 0.11% in the last 4 weeks and 30.88% in the past three months. Over the past 5 trading sessions the stock has lost 1.85%. Shares of the $178.75 billion market cap Seattle-Washington-based e-commerce giant are up 16.03% year-over-year and 21.01% year-to-date.

Eagle Pharmaceuticals Inc. (EGRX) rating of ‘Overweight’ was reiterated today at Piper Jaffray with a price target increase of $75 from $55 (versus a $55.44 previous close).

In the past 52 weeks, shares of Woodcliff Lake, New Jersey-based specialty pharmaceutical company have traded between a low of $9.16 and a high of $62.00 and are now at $59.32. Shares are up 348.91% year-over-year and 257.68% year-to-date.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.